EW (Edwards Lifesciences) Ending Cash Position: $2,448 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

EW Edwards Lifesciences Corp EW
97 GF Score
Price $85.00
GF Value $93.79
Valuation Fairly Valued
! 5 Warning Signs
View Full Analysis

What is Edwards Lifesciences Ending Cash Position?

Edwards Lifesciences EW -0.85% 97 Ending Cash Position is $2,448 Mil as of Mar. 2026. GuruFocus rates EW with a GF Score™ of 97/100 and a GF Value™ of $93.79 (Fairly Valued). The stock has 5 warning signs investors should review.

Edwards Lifesciences's Ending Cash Position for the quarter that ended in Mar. 2026 was $2,448 Mil.

Edwards Lifesciences's quarterly Ending Cash Position increased from Sep. 2025 ($2,695 Mil) to Dec. 2025 ($2,940 Mil) but then declined from Dec. 2025 ($2,940 Mil) to Mar. 2026 ($2,448 Mil).

Edwards Lifesciences's annual Ending Cash Position increased from Dec. 2023 ($1,148 Mil) to Dec. 2024 ($3,059 Mil) but then declined from Dec. 2024 ($3,059 Mil) to Dec. 2025 ($2,940 Mil).


Edwards Lifesciences Ending Cash Position Related Terms


Edwards Lifesciences Ending Cash Position Historical Data

* Premium members only.

The historical data trend for Edwards Lifesciences's Ending Cash Position can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Edwards Lifesciences Ending Cash Position Chart

Edwards Lifesciences Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Ending Cash Position
Get a 7-Day Free Trial Premium Member Only Premium Member Only 867.40 772.60 1,148.00 3,058.80 2,939.50

Edwards Lifesciences Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Ending Cash Position Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 3,148.80 3,290.00 2,694.80 2,939.50 2,447.50
EW
97GF Score
Edwards Lifesciences Corp EW
Ending Cash Position is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Edwards Lifesciences Ending Cash Position Calculation

Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. It is equal to the Beginning Cash Position plus the Net Change in Cash.

Edwards Lifesciences's Ending Cash Position for the fiscal year that ended in Dec. 2025 is calculated as

Ending Cash Position= Beginning Cash Position+Net Change in Cash
=3058.8+-119.3
=2,940

Edwards Lifesciences's Ending Cash Position for the quarter that ended in Mar. 2026 is calculated as

Ending Cash Position=Beginning Cash Position+Net Change in Cash
=2939.5+-492
=2,448

Frequently Asked Questions Learn more about Ending Cash Position →
What does a Ending Cash Position of $2,448 Mil mean?
Edwards Lifesciences (EW) has a Ending Cash Position of $2,448 Mil as of Mar. 2026. Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. View historical data on Edwards Lifesciences and its competitors.
Is Edwards Lifesciences' Ending Cash Position too high?
Edwards Lifesciences' current Ending Cash Position is $2,448 Mil. Overall, Edwards Lifesciences has a GF Score™ of 97/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Edwards Lifesciences' Ending Cash Position compare to BSX and GEHC?
Edwards Lifesciences' Ending Cash Position of $2,448 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Ending Cash Position for a Medical Devices & Instruments company?
A good Ending Cash Position depends on the Medical Devices & Instruments industry context. However, Ending Cash Position should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Ending Cash Position mean?
A high Ending Cash Position can signal that a stock is expensive relative to its fundamentals. Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. View historical data on Edwards Lifesciences and its competitors. Edwards Lifesciences's current Ending Cash Position is $2,448 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Edwards Lifesciences stock overvalued right now?
Based on GuruFocus' analysis, Edwards Lifesciences (EW) is currently considered Fairly Valued. The stock's GF Value™ is $93.79, compared to a current price of $85.00 — trading 9.4% below its estimated fair value. The current Ending Cash Position is $2,448 Mil. Edwards Lifesciences' overall GF Score™ is 97/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Ending Cash Position calculated?
Ending Cash Position is calculated from a company's financial statements. For Edwards Lifesciences (EW), the current Ending Cash Position is $2,448 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Edwards Lifesciences (EW) Overvalued in 2026?

Based on GuruFocus' analysis, Edwards Lifesciences stock appears to be undervalued. The current stock price of $85.00 is trading 9.4% below its estimated GF Value™ of $93.79. GuruFocus considers Edwards Lifesciences to be Fairly Valued.

Key valuation signals for EW:

  • Ending Cash Position: $2,448 Mil
  • GF Value™: $93.79 vs. price of $85.00 (9.4% below fair value)
  • GF Score™: 97/100 with 5 warning signs

No single metric tells the full story. See the EW stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Edwards Lifesciences Business Description

Address One Edwards Way, Irvine, CA, USA, 92614
Spun off from Baxter International in 2000, Edwards Lifesciences designs, manufactures, and markets a range of medical devices and equipment for advanced stages of structural heart disease. It has established itself as a leader across key products, including surgical tissue heart valves, transcatheter aortic valves, and transcatheter mitral and tricuspid valve technologies. The firm derives about 60% of its total sales from outside the US.
97GF Score

Get the complete analysis for EW

Ending Cash Position is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$85.00
Price
$93.79
GF Value